Oruka Therapeutics, Inc. — Director's Dealing 2012

Oct 25, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-10-22

Reporting Person: Ozeroff Christopher David (SVP and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-10-22	Common Stock	A	63475	$.3939	Acquired	105233	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-10-22	Common Stock Warrant (right to buy)	$.3001	A	47606	Acquired	2017-10-25	Common Stock (47606)	Direct

Footnotes

F1: The warrants are fully vested and exercisable upon issuance and have a contractual term of 5 years.